Trial Profile

A Phase 2, Randomized, Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Claseprubart (Primary)
Indications Myasthenia gravis
Focus Adverse reactions; Therapeutic Use
Acronyms MAGIC
Sponsors Dianthus Therapeutics

Most Recent Events

08 Jun 2026 Planned End Date changed from 1 Aug 2027 to 1 Oct 2028.
05 May 2026 According to a Dianthus Therapeutics media release, the company announced the successful completion of our end-of-Phase 2 meeting with the FDA in the first quarter of 2026
05 May 2026 According to a Dianthus Therapeutics media release, data from this study were presented at the 2026 American Academy of Neurology (AAN) Annual Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com